Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director | December 31, 2019 | January 03, 2020 |
| EAGLE PHARMACEUTICALS, INC.EGRX · Entity 85958 | 10% owner | February 28, 2024 | March 01, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date December 31, 2019 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2029-12-31 | Direct | 50,562 |
Reported balance
After 2019-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-31 · Grant · Acquired 50,562 · Balance 50,562 F1: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date.
EAGLE PHARMACEUTICALS, INC.
Report date February 28, 2024 · Filed March 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 460,621 |
Reported balance
After 2024-02-28 transaction · row 1
1 source rowRow 1 · 2024-02-28 · Tax withholding · Disposed 2,119 · Balance 460,621 F1: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on February 28, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 | 992,623 |
Reported balance
Holding disclosure · report date 2024-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 992,623 F2: Shares held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest, if any, therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on February 28, 2024.
F2: Shares held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest, if any, therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theriva Biologics, Inc.
Report date November 11, 2020 · Filed November 12, 2020
Section 16 reporting ended · disclosed 2020-11-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2018 Filed Jan 9, 2018 17:50 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantEmployee Stock Option (Right to Buy) · Derivative | 157,000 | $0.00 Strike: $59.14 | $0.00 |
DisclosureSEC source: 0001209191-18-003005 · doc4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,000 Underlying: Common Stock · 157,000 shares Expires 2028-01-07 F1 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 7, 2019, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:00 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantOption Grant (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001209191-18-001017 · doc4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-12-29 F1 · derivative.exercise_date: 25,000 shares shall vest on 12/29/2018. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:18 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001144204-17-064824 · tv481800_4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2024-12-19 F1 · shares: These stock options vest in full on the one year anniversary of the grant date. F1 · derivative.exercise_date: These stock options vest in full on the one year anniversary of the grant date. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:10 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantStock Option (right to buy) · Derivative | 200,900 | $0.00 Strike: $84.92 | $0.00 |
DisclosureSEC source: 0001209191-17-002689 · doc4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,900 Underlying: Common Stock · 200,900 shares Expires 2027-01-03 F1 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 4, 2018, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 21:37 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-17-000968 · doc4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-30 F1 · derivative.exercise_date: 25,000 shares shall vest on 12/30/2017. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:07 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 168,750 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001144204-16-137744 · v454264_4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2023-11-29 F1 · shares: These stock options vest as follows: 1/3 vested on the grant date, 1/3 will vest on the one year anniversary of the grant date and the remaining 1/3 will vest on the two year anniversary of the grant date. F1 · derivative.exercise_date: These stock options vest as follows: 1/3 vested on the grant date, 1/3 will vest on the one year anniversary of the grant date and the remaining 1/3 will vest on the two year anniversary of the grant date. Read SEC document |
| November 18, 2016 Filed Nov 18, 2016 16:12 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantSeries B Warrant · Derivative | 300,000 | Not disclosed Strike: $1.72 | Not disclosed |
DisclosureSEC source: 0001144204-16-135295 · v453318_4.xml · derivative · entry 3 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2017-12-31 F1 · price: The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00. F1 · derivative.exercise_date: The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00. Read SEC document |
| November 18, 2016 Filed Nov 18, 2016 16:12 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantSeries A Warrant · Derivative | 300,000 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001144204-16-135295 · v453318_4.xml · derivative · entry 2 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2020-11-18 F1 · price: The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00. F1 · derivative.exercise_date: The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00. Read SEC document |
| November 18, 2016 Filed Nov 18, 2016 16:12 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantCommon Stock | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-16-135295 · v453318_4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · price: The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.